Tier 3 — preclinical

SIRT6 promotes intrahepatic cholangiocarcinoma development by reprogramming glutamine metabolism via enhanced GLUL

Mi Zhang, Chanyuan Chen, Haifeng Zhang, Tanqing Long, Tingjie Wang, Nanjin Ding, Ruitao Long, Hua Wu, Zhilu Ma, Zhongyu Cheng, Junyan Tao, Dong Kuang, Lei Li, Chuanrui Xu
Gut 2026 75(7):1383-1396

Bibliography

PubMed
PMID 41136182

Study snapshot

DesignSpatial/single-cell human tumor analysis plus mechanistic cell experiments and allograft/primary mouse ICC models.
ModelHuman intrahepatic cholangiocarcinoma samples and datasets, ICC cell lines, allografts and AKT/YAP-induced primary ICC mice.
SampleMultiple clinical datasets/specimens and mouse experiments; exact totals vary by analysis.
InterventionSIRT6 knockdown/overexpression and SIRT6 or GLUL inhibition.
DurationModel-specific experimental durations.
EndpointsTumor growth; SIRT6 expression; GLUL transcription and protein stability; Glutamine synthesis; Nucleotide and amino-acid levels; Chemotherapy sensitivity

What the study showed, in plain terms

Unlike cancers where SIRT6 suppresses growth, this 2026 study found that SIRT6 was highly expressed in intrahepatic cholangiocarcinoma and actively drove tumor growth by increasing GLUL-dependent glutamine production.

Key findings

SIRT6 knockdown inhibited ICC growth, while SIRT6 co-expression with AKT drove ICC formation in mice. SIRT6 enhanced GLUL transcription and stability, rewiring glutamine metabolism; inhibiting SIRT6 or GLUL suppressed progression and improved chemotherapy sensitivity.

What this study can and cannot tell us

The study is specific to intrahepatic cholangiocarcinoma and does not establish that systemic SIRT6 activation increases cancer risk generally. It does, however, strongly refute universal tumor-suppressor framing.

Citation network

Articles citing this research paper

5 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified